Picture [LSA] Life-Sciences-Asia.com – The Business Web Portal 650x89px

Organisation › Details

JSR Corporation (Group)

http://www.jsr.co.jp

	Start	1957-12-10 established
	Industry	LIFE SCIENCES

	Region	Tokyo
	Country	Japan
	Street	1-9-2 Higashi-Shimbashi Minato-ku
	City	105-8640 Tokyo
		Address record changed: 2019-06-22

Basic data	Employees	G: 5,001 to 10,000 (2018-03-31)


		Record changed: 2019-06-22

More documents for JSR Corporation (Group)

[1] Selexis S.A.. (6/20/19). "Press Release: Avacta and Selexis Partner to Develop Cell Line for Clinical Manufacturing". Cambridge & Geneva....
[2] Selexis S.A.. (3/28/19). "Press Release: Selexis Bolsters Business Development Team to Support Expanding Base of Partners Relying on Its SUREtechnology to Advance Complex Biologics and Vaccines". Geneva....
[3] Selexis S.A.. (1/9/19). "Press Release: Selexis Expands Strategic Immuno-Oncology Alliance with Agenus". Geneva....
[4] Selexis S.A.. (1/4/19). "Press Release: Selexis SA to Participate at Several Upcoming Industry Conferences". Geneva....
[5] Selexis S.A.. (12/17/18). "Press Release: TeneoBio and Selexis Enter Second Services Agreement to Develop Research Cell Banks". Geneva & Menlo Park, CA....
[6] Selexis S.A.. (12/3/18). "Press Release: KBI Biopharma Inc. and Selexis SA Form Joint Scientific Advisory Board". Durham, NC & Geneva....
[7] Selexis S.A.. (10/18/18). "Press Release: Selexis and Berkeley Lights Collaborate to Accelerate Cell Line Development with the Beacon Optofluidic Platform". Geneva....
[8] CytoSen Therapeutics, Inc.. (10/2/18). "Press Release: CytoSen Therapeutics and KBI Biopharma Enter into Strategic Partnership to Manufacture NK Cells and Nanoparticles". Dallas, TX & Durham, NC....
[9] Selexis S.A.. (3/7/18). "Press Release: Compugen Has Licensed Selexis’ Cell Line-Based Protein Expression Platform for the Development of Antibody-Based Therapeutics". Geneva....
[10] Selexis S.A.. (2/26/18). "Press Release: Xencor Signs Four Commercial License Agreements with Selexis SA to Advance its Pipeline of XmAb Bispecific Antibody Drug Candidates". Geneva....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]